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Introduction
Mesenchymal stromal cells (MSC) are multipotent cells
with an immunosuppressive capacity. In the last decade
the feasibility and safety of MSC therapy has been
established in various inflammatory diseases, including
graft versus host disease. MSC are known to suppress
T cell function and modulate T helper 17 (Th17) cells and
regulatory T cells (Tregs), which play an important role in
the pathogenesis of juvenile idiopathic arthritis (JIA). MSC
may therefore serve as a new treatment option for JIA
patients refractory to conventional therapies. However, it
is unknown whether MSC are capable of suppressing the
highly inflammatory synovial fluid mononuclear cells
(SFMC), which have been shown to be resistant to
suppression by Tregs. Furthermore, the effect of
the inflammatory environment on MSC function is
largely unknown, though it has been suggested that
proinflammatory cytokines can enhance the suppres-
sive potential of MSC.
Objectives
We aimed to study the in vitro immunomodulatory
effects of MSC on SFMC from JIA patients, with a focus
on T cell function. In addition, we assessed the influence
of the inflammatory micro-environment, i.e. monocytes
and proinflammatory cytokines, on the suppressive
potential of MSC.
Methods
MSC were cocultured with either peripheral blood
mononuclear cells (PBMC) or synovial fluid mononuclear
cells (SFMC) from JIA patients (paired samples) or
PBMC from healthy controls. We analyzed the effect of
MSC on T cell proliferation and Th17 and Treg numbers
by flow cytometry. Cytokine production was analyzed in
the culture supernatant by Luminex assay. Furthermore,
we depleted monocytes from culture and blocked the
proinflammatory cytokines TNFa, IFNg, IL-1b and IL-6 to
assess the result on MSC-mediated suppression.
Results
MSC suppressed proliferation of PB T cells and SF T cells
from JIA patients dose-dependently, but patient-derived
T cells were less susceptible to suppression than healthy
donor-derived T cells. MSC reduced Th17 numbers and
increased Treg numbers in PBMC, but not in SFMC.
Addition of MSC did not clearly affect IL-17 levels in the
supernatant, but TNFa production was suppressed in
both PBMC and SFMC. Contrary to previous reports,
blockade of TNFa, IFNg, IL-1b and IL-6 during in vitro
culture did not reduce suppression, but rather enhanced
suppression in PBMC from JIA patients. Similarly, deple-
tion of monocytes increased MSC-dependent suppression
of healthy control PB T cells.
Conclusion
MSC suppress proliferation of synovial fluid T cells from
JIA patients in a dose-dependent manner. However,
patient-derived T cells are less susceptible to immunomo-
dulation than healthy donor T cells. We propose that
reduction of proinflammatory stimuli in conjunction with
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